SG11201804674UA - Heteroarylhydroxypyrimidinones as agonists of the apj receptor - Google Patents
Heteroarylhydroxypyrimidinones as agonists of the apj receptorInfo
- Publication number
- SG11201804674UA SG11201804674UA SG11201804674UA SG11201804674UA SG11201804674UA SG 11201804674U A SG11201804674U A SG 11201804674UA SG 11201804674U A SG11201804674U A SG 11201804674UA SG 11201804674U A SG11201804674U A SG 11201804674UA SG 11201804674U A SG11201804674U A SG 11201804674UA
- Authority
- SG
- Singapore
- Prior art keywords
- pennington
- bristol
- new jersey
- international
- myers
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267997P | 2015-12-16 | 2015-12-16 | |
| PCT/US2016/066750 WO2017106396A1 (en) | 2015-12-16 | 2016-12-15 | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804674UA true SG11201804674UA (en) | 2018-06-28 |
Family
ID=57708840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804674UA SG11201804674UA (en) | 2015-12-16 | 2016-12-15 | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
Country Status (21)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36705A (es) | 2015-06-03 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj |
| BR112018007395A2 (pt) | 2015-10-14 | 2018-10-23 | Bristol-Myers Squibb Company | 2,4-di-hidróxi-nicotinamidas como agonistas de apj |
| AU2016365340B2 (en) | 2015-12-04 | 2021-05-27 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
| SG11201805044WA (en) | 2015-12-16 | 2018-07-30 | Loxo Oncology Inc | Compounds useful as kinase inhibitors |
| MX379088B (es) | 2016-03-24 | 2025-03-10 | Bristol Myers Squibb Co | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj). |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| CN109311821B (zh) * | 2016-06-14 | 2022-10-14 | 百时美施贵宝公司 | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 |
| CN109641843B (zh) | 2016-06-14 | 2022-07-19 | 百时美施贵宝公司 | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 |
| KR102521956B1 (ko) | 2016-10-14 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제 |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| US6174998B1 (en) | 1996-03-12 | 2001-01-16 | Roche Diagnostics Gmbh | C-nucleoside derivatives and their use in the detection of nucleic acids |
| JPH08311041A (ja) | 1995-03-16 | 1996-11-26 | Takeda Chem Ind Ltd | 複素環化合物およびその剤 |
| US5985884A (en) | 1996-07-01 | 1999-11-16 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| US6369067B1 (en) | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| WO2001060805A1 (en) * | 2000-02-16 | 2001-08-23 | Smithkline Beecham P.L.C. | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
| WO2002006242A2 (en) | 2000-07-18 | 2002-01-24 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
| WO2002081454A1 (en) | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| MXPA04011074A (es) | 2002-05-09 | 2005-06-08 | Cytokinetics Inc | Compuestos de pirimidinona, composiciones y metodos. |
| JP2005530806A (ja) | 2002-05-23 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害薬 |
| US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| WO2004094408A1 (en) | 2003-04-23 | 2004-11-04 | Pharmacia & Upjohn Company Llc | Substituted pyrimidinones and pyrimidinthiones as crf antagonists |
| JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| WO2005041888A2 (en) | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
| EP1697331A4 (en) | 2003-12-19 | 2010-08-04 | Merck Sharp & Dohme | INHIBITORS OF MITOTIC KINESINE |
| JP4517349B2 (ja) | 2004-07-28 | 2010-08-04 | 宇部興産株式会社 | ピリミジン−４−オン化合物の製造方法 |
| DE102005025315A1 (de) | 2005-06-02 | 2006-12-14 | Merck Patent Gmbh | Ionische Flüssigkeiten mit niedriger Viskosität |
| WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| EP2016056A4 (en) | 2006-04-21 | 2010-11-10 | Univ Boston | IONIC VISCOELASTIC AND VISCOELASTIC SALTS |
| WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
| EP2079707B1 (de) | 2006-10-10 | 2014-12-03 | proionic GmbH & Co KG | Verfahren zur umsetzung von 1,3-hetero-aromatischen 2-carboxylaten mit wasser |
| WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| EP2279192B1 (en) | 2008-05-28 | 2013-10-30 | Merck Patent GmbH | Ionic liquids |
| DE102008031480A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Salze enthaltend ein Pyrimidincarbonsäure-Derivat |
| WO2010072696A2 (de) | 2008-12-22 | 2010-07-01 | Basf Se | Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern |
| EP2432776B1 (en) | 2009-05-21 | 2019-09-11 | Universite Laval | Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics |
| EP2604260B1 (en) | 2010-08-10 | 2017-05-10 | Shionogi&Co., Ltd. | Novel heterocyclic derivatives and pharmaceutical composition containing same |
| KR20140039242A (ko) | 2011-05-31 | 2014-04-01 | 메르크 파텐트 게엠베하 | 전해질 제형 |
| US9518068B2 (en) | 2011-05-31 | 2016-12-13 | Merck Patent Gmbh | Compounds containing hydrido-tricyano-borate anions |
| CN102903954B (zh) | 2011-07-25 | 2015-06-03 | 微宏动力系统（湖州）有限公司 | 含有离子液体电解质的锂离子二次电池 |
| DE102012006896A1 (de) | 2012-04-05 | 2013-10-10 | Merck Patent Gmbh | Silikate mit organischen Kationen |
| AU2013271731A1 (en) | 2012-06-07 | 2014-12-18 | Georgia State University Research Foundation, Inc. | SecA inhibitors and methods of making and using thereof |
| DK2897939T3 (en) * | 2012-09-21 | 2017-05-08 | Sanofi Sa | BENZOIMIDAZOLCARBOXYL ACID AMIDE DERIVATIVES FOR THE TREATMENT OF METABOLIC OR CARDIOVASCULAR DISEASES |
| WO2014056844A1 (en) | 2012-10-10 | 2014-04-17 | Basf Se | Ionic liquids based on oxalic acid mono esters |
| DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
| AU2013344422A1 (en) | 2012-11-16 | 2015-07-02 | Biocryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
| WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
| DE102013016324A1 (de) | 2013-10-04 | 2015-04-09 | Merck Patent Gmbh | Perfluoralkylfluor- oder Perfluoralkylchlorgermanate |
| ES2906062T3 (es) | 2013-11-29 | 2022-04-13 | Proionic Gmbh | Procedimiento para la unión de un material termoplástico por medio de radiación de microondas |
| KR101550846B1 (ko) | 2014-01-29 | 2015-09-07 | 한국과학기술연구원 | 단일공정을 이용한 탄소소재의 다원소 도핑방법 및 그 용도 |
| KR101531023B1 (ko) | 2014-05-27 | 2015-06-23 | 한국과학기술연구원 | 열분해 가스 도핑에 의한 고강도 고전도성 탄소나노튜브섬유의 제조방법 및 이에 따라 제조된 탄소나노튜브섬유 |
| US10570128B2 (en) | 2014-05-28 | 2020-02-25 | Sanford Burnham Prebys Medical Discovery Institute | Agonists of the apelin receptor and methods of use thereof |
| KR102509043B1 (ko) * | 2014-06-06 | 2023-03-09 | 리써치 트라이앵글 인스티튜트 | 아펠린 수용체(apj) 효능제 및 이의 용도 |
| WO2016074757A1 (de) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren |
| UY36705A (es) * | 2015-06-03 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj |
| BR112018007395A2 (pt) | 2015-10-14 | 2018-10-23 | Bristol-Myers Squibb Company | 2,4-di-hidróxi-nicotinamidas como agonistas de apj |
| AU2016365340B2 (en) | 2015-12-04 | 2021-05-27 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
| MX379088B (es) | 2016-03-24 | 2025-03-10 | Bristol Myers Squibb Co | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj). |
| CN109641843B (zh) | 2016-06-14 | 2022-07-19 | 百时美施贵宝公司 | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 |
| CN109311821B (zh) | 2016-06-14 | 2022-10-14 | 百时美施贵宝公司 | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 |
| KR102521956B1 (ko) | 2016-10-14 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제 |
-
2016
- 2016-12-15 JP JP2018531333A patent/JP6948322B2/ja active Active
- 2016-12-15 ES ES16820507T patent/ES2854733T3/es active Active
- 2016-12-15 EA EA201891336A patent/EA036736B1/ru not_active IP Right Cessation
- 2016-12-15 US US16/061,365 patent/US10669261B2/en active Active
- 2016-12-15 UY UY0001037026A patent/UY37026A/es unknown
- 2016-12-15 SG SG11201804674UA patent/SG11201804674UA/en unknown
- 2016-12-15 TW TW105141572A patent/TW201725203A/zh unknown
- 2016-12-15 HK HK18114280.0A patent/HK1255163A1/zh unknown
- 2016-12-15 EP EP16820507.8A patent/EP3390400B1/en active Active
- 2016-12-15 PE PE2018001129A patent/PE20181487A1/es unknown
- 2016-12-15 MX MX2018007155A patent/MX380669B/es unknown
- 2016-12-15 CN CN201680081704.3A patent/CN108602813B/zh active Active
- 2016-12-15 AU AU2016372048A patent/AU2016372048B2/en not_active Ceased
- 2016-12-15 CA CA3008630A patent/CA3008630A1/en not_active Abandoned
- 2016-12-15 BR BR112018012112-6A patent/BR112018012112A2/pt not_active Application Discontinuation
- 2016-12-15 WO PCT/US2016/066750 patent/WO2017106396A1/en active Application Filing
- 2016-12-15 KR KR1020187019799A patent/KR102742744B1/ko active Active
- 2016-12-15 AR ARP160103867A patent/AR107061A1/es unknown
-
2018
- 2018-06-11 IL IL259947A patent/IL259947B/en active IP Right Grant
- 2018-06-15 CL CL2018001621A patent/CL2018001621A1/es unknown
- 2018-07-11 CO CONC2018/0007221A patent/CO2018007221A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3390400A1 (en) | 2018-10-24 |
| IL259947A (en) | 2018-07-31 |
| UY37026A (es) | 2017-06-30 |
| PE20181487A1 (es) | 2018-09-18 |
| CO2018007221A2 (es) | 2018-07-19 |
| AR107061A1 (es) | 2018-03-14 |
| HK1255163A1 (zh) | 2019-08-09 |
| CN108602813B (zh) | 2021-10-29 |
| CL2018001621A1 (es) | 2018-08-03 |
| US10669261B2 (en) | 2020-06-02 |
| AU2016372048B2 (en) | 2021-02-04 |
| KR20180095577A (ko) | 2018-08-27 |
| ES2854733T3 (es) | 2021-09-22 |
| MX2018007155A (es) | 2018-08-15 |
| EA036736B1 (ru) | 2020-12-14 |
| CA3008630A1 (en) | 2017-06-22 |
| EA201891336A1 (ru) | 2019-01-31 |
| JP2018538304A (ja) | 2018-12-27 |
| CN108602813A (zh) | 2018-09-28 |
| BR112018012112A2 (pt) | 2018-12-04 |
| WO2017106396A1 (en) | 2017-06-22 |
| TW201725203A (zh) | 2017-07-16 |
| JP6948322B2 (ja) | 2021-10-13 |
| MX380669B (es) | 2025-03-12 |
| KR102742744B1 (ko) | 2024-12-12 |
| EP3390400B1 (en) | 2021-01-20 |
| US20180362508A1 (en) | 2018-12-20 |
| AU2016372048A1 (en) | 2018-08-02 |
| IL259947B (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201808163WA (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909918XA (en) | Compositions and methods for improving sample identification in indexed nucleic acid libraries | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201808215SA (en) | Aluminum alloys having iron, silicon, vanadium and copper, and with a high volume of ceramic phase therein | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors |